DR. DATSONS LABS | JUBILANT LIFE SCIENCES | DR. DATSONS LABS/ JUBILANT LIFE SCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -10.9 | 17.3 | - | View Chart |
P/BV | x | 0.2 | 3.2 | 5.0% | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
JUBILANT LIFE SCIENCES Mar-19 |
DR. DATSONS LABS/ JUBILANT LIFE SCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 898 | 14.0% | |
Low | Rs | 31 | 618 | 5.0% | |
Sales per share (Unadj.) | Rs | 133.0 | 572.0 | 23.3% | |
Earnings per share (Unadj.) | Rs | 0.2 | 36.2 | 0.4% | |
Cash flow per share (Unadj.) | Rs | 6.6 | 59.5 | 11.1% | |
Dividends per share (Unadj.) | Rs | 0 | 4.50 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.6 | 0.0% | |
Book value per share (Unadj.) | Rs | 128.8 | 301.9 | 42.7% | |
Shares outstanding (eoy) | m | 31.66 | 159.28 | 19.9% | |
Bonus/Rights/Conversions | FCCB | - | - | ||
Price / Sales ratio | x | 0.6 | 1.3 | 44.4% | |
Avg P/E ratio | x | 516.1 | 20.9 | 2,467.5% | |
P/CF ratio (eoy) | x | 11.8 | 12.7 | 93.0% | |
Price / Book Value ratio | x | 0.6 | 2.5 | 24.2% | |
Dividend payout | % | 0 | 12.4 | 0.0% | |
Avg Mkt Cap | Rs m | 2,477 | 120,694 | 2.1% | |
No. of employees | `000 | NA | 2.4 | 0.0% | |
Total wages/salary | Rs m | 56 | 19,260 | 0.3% | |
Avg. sales/employee | Rs Th | NM | 38,120.6 | - | |
Avg. wages/employee | Rs Th | NM | 8,058.4 | - | |
Avg. net profit/employee | Rs Th | NM | 2,414.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 91,108 | 4.6% | |
Other income | Rs m | 79 | 357 | 22.0% | |
Total revenues | Rs m | 4,289 | 91,466 | 4.7% | |
Gross profit | Rs m | 569 | 17,390 | 3.3% | |
Depreciation | Rs m | 204 | 3,709 | 5.5% | |
Interest | Rs m | 430 | 2,198 | 19.6% | |
Profit before tax | Rs m | 13 | 11,840 | 0.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -2,802 | 0.0% | |
Tax | Rs m | 6 | 3,268 | 0.2% | |
Profit after tax | Rs m | 5 | 5,770 | 0.1% | |
Gross profit margin | % | 13.5 | 19.1 | 70.8% | |
Effective tax rate | % | 48.0 | 27.6 | 174.0% | |
Net profit margin | % | 0.1 | 6.3 | 1.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 45,848 | 14.9% | |
Current liabilities | Rs m | 6,711 | 20,897 | 32.1% | |
Net working cap to sales | % | 3.3 | 27.4 | 12.2% | |
Current ratio | x | 1.0 | 2.2 | 46.5% | |
Inventory Days | Days | 161 | 57 | 283.2% | |
Debtors Days | Days | 318 | 51 | 625.2% | |
Net fixed assets | Rs m | 3,673 | 65,498 | 5.6% | |
Share capital | Rs m | 317 | 159 | 198.7% | |
"Free" reserves | Rs m | 3,761 | 47,930 | 7.8% | |
Net worth | Rs m | 4,078 | 48,089 | 8.5% | |
Long term debt | Rs m | 1,671 | 42,429 | 3.9% | |
Total assets | Rs m | 12,633 | 114,685 | 11.0% | |
Interest coverage | x | 1.0 | 6.4 | 16.1% | |
Debt to equity ratio | x | 0.4 | 0.9 | 46.4% | |
Sales to assets ratio | x | 0.3 | 0.8 | 42.0% | |
Return on assets | % | 3.4 | 6.9 | 49.6% | |
Return on equity | % | 0.1 | 12.0 | 1.0% | |
Return on capital | % | 7.7 | 12.4 | 61.8% | |
Exports to sales | % | 22.9 | 0 | - | |
Imports to sales | % | 14.3 | 0 | - | |
Exports (fob) | Rs m | 964 | NA | - | |
Imports (cif) | Rs m | 602 | NA | - | |
Fx inflow | Rs m | 964 | 12,422 | 7.8% | |
Fx outflow | Rs m | 607 | 17,227 | 3.5% | |
Net fx | Rs m | 357 | -4,805 | -7.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | 11,215 | 12.0% | |
From Investments | Rs m | -2,256 | -10,118 | 22.3% | |
From Financial Activity | Rs m | -1,200 | 6,574 | -18.2% | |
Net Cashflow | Rs m | -2,111 | 7,612 | -27.7% |
Indian Promoters | % | 4.5 | 45.6 | 9.9% | |
Foreign collaborators | % | 0.0 | 3.5 | - | |
Indian inst/Mut Fund | % | 0.0 | 8.7 | - | |
FIIs | % | 1.4 | 21.2 | 6.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 94.1 | 21.1 | 446.0% | |
Shareholders | 20,807 | 23,815 | 87.4% | ||
Pledged promoter(s) holding | % | 0.0 | 15.9 | - |
Compare DR. DATSONS LABS With: PIRAMAL ENTERPRISES GSK PHARMA FRESENIUS KABI ONCO. DR. REDDYS LAB NOVARTIS
Compare DR. DATSONS LABS With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.
For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.
For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.
For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.
Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.
For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More